Keyword Analysis & Research: imfinzi ema

europa.eu

https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi

WebIMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ? 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).

DA: 65 PA: 48 MOZ Rank: 72

europa.eu

https://www.ema.europa.eu/en/medicines/human/variation/imfinzi

WebJul 26, 2020 · On 12 October 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Imfinzi.

DA: 70 PA: 100 MOZ Rank: 13

europa.eu

https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf

WebIMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (see section 5.1).

DA: 76 PA: 85 MOZ Rank: 36

europa.eu

https://www.ema.europa.eu/en/medicines/human/summaries-opinion/imfinzi-0

WebEuropean Medicines Agency

DA: 47 PA: 64 MOZ Rank: 67

astrazeneca.com

https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-imjudo-approved-in-the-eu-for-patients-with-advanced-liver-and-non-small-cell-lung-cancers.html

WebFeb 22, 2023 · AstraZeneca’s Imfinzi (durvalumab) and Imjudo (tremelimumab) immunotherapy combinations have been approved in the European Union (EU) for the treatment of advanced liver and lung cancers.

DA: 7 PA: 41 MOZ Rank: 34

digital-astrazeneca.com

https://od-prod-origin-astrazeneca-corporate.digital-astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-recommended-for-approval-in-the-eu-by-chmp-as-first-immunotherapy-regimen-for-advanced-biliary-tract-cancer.html

Web14 November 2022 07:05 GMT. Positive opinion based on TOPAZ-1 Phase III trial updated survival results showing Imfinzi combination reduced risk of death by 24% vs. chemotherapy alone.

DA: 100 PA: 84 MOZ Rank: 62

europa.eu

https://ec.europa.eu/health/documents/community-register/2022/20220822156563/anx_156563_en.pdf

WebIMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (see section 5.1).

DA: 48 PA: 86 MOZ Rank: 23

astrazeneca.com

https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-approved-in-eu-for-biliary-tract-cancer.html

WebDec 21, 2022 · Approval based on TOPAZ-1 updated survival results showing Imfinzicombination reduced risk of death by 24% vs. chemotherapy alone. AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the 1st-line treatment of adult patients with unresectable or metastatic biliary tract cancer (BTC) in …

DA: 12 PA: 51 MOZ Rank: 8

europa.eu

https://www.ema.europa.eu/en/documents/overview/imfinzi-epar-medicine-overview_en.pdf

WebEMA/949093/2022 EMEA/H/C/004771. Imfinzi (durvalumab) An overview of Imfinzi and why it is authorised in the EU. What is Imfinzi and what is it used for? Imfinzi is a medicine used to treat lung cancer. It is for use in adults with:

DA: 35 PA: 10 MOZ Rank: 4

wikipedia.org

https://en.wikipedia.org/wiki/Durvalumab

WebDurvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 ( PD-L1 ) with the PD-1 (CD279). ema

ema

DA: 80 PA: 39 MOZ Rank: 19